Cancer Community News

Cancer Community News

  • 10/20/2016
    Announcements, events, and opportunities for members of the Cancer Community @ Illinois.
  • Cancer Community Annual Meeting Engaged Researchers and Clinical Partners
    10/20/2016
    The Cancer Community at Illinois’ Annual Meeting was held Wednesday, October 19 at the Beckman Institute. More than 60 people gathered for a productive morning of updates on the Cancer Community at Illinois' activities and plans. Attendees also heard from leaders in the field, including new Carle Illinois College of Medicine Dean King Li, and had the opportunity to network with researchers and clinicians. A report on the meeting will be made available in the coming weeks.
  • 10/20/2016Ashley Lawrence writer Ashley Lawrence by Ashley Lawrence published by Ashley Lawrence
  • 10/13/2016
    Announcements, events, and opportunities for members of the Cancer Community @ Illinois.
  • 10/11/2016

    Across the globe, the most frequent form of diagnosed cancer is breast cancer. Nearly 75% of those diagnoses feature tumors that test positive for estrogen receptors (ER), a group of proteins within the cancer cells that are activated by estrogen.

    Tamoxifen is one of the best drugs to fight against breast cancer and has been for more than 40 years, according to University of Illinois Researcher Zeynep Madak-Erdogan. But not all patients react the same way to tamoxifen.

    Madak-Erdogan and a team of Illinois researchers recently discovered why.

    In an article published online in the Journal of Molecular Endocrinology, the team shares that patients with high levels of several specific nuclear transport genes are more likely to be resistant to tamoxifen. With that knowledge, the team discovered that combining tamoxifen with selinexor—a second drug that prevents the activity of one of those genes—increases patients’ sensitivity to tamoxifen and prevents the recurrence of breast tumors.